Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease
;
: 294-296, 2015.
Article
in Korean
| WPRIM
| ID: wpr-83768
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sigmoid Neoplasms
/
United States Food and Drug Administration
/
Immunoglobulins
/
Desensitization, Immunologic
/
Cetuximab
/
Hypersensitivity
/
Anaphylaxis
Type of study:
Practice guideline
Limits:
Aged
/
Humans
/
Male
Language:
Korean
Journal:
Allergy, Asthma & Respiratory Disease
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS